NDABUCCALGUM, CHEWING
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
NICORETTE (MINT) (nicotine polacrilex) by GSK. Approved for nicotine dependence, cigarette smoking behavior. First approved in 1992.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NICORETTE (MINT) is a nicotine polacrilex chewing gum formulation indicated for nicotine dependence and cigarette smoking cessation. It functions as a cholinergic nicotinic agonist that binds to nicotinic receptors in the CNS, providing stimulant and reward effects to reduce cravings and withdrawal symptoms. The buccal gum delivery enables patient self-titration and flexible dosing for smoking cessation.
LOE Approaching2.0 years to LOE
Product approaching loss of exclusivity in 2028 with formulation patent expiration; teams likely transitioning focus to life-cycle extensions, generic preparation, or portfolio rationalization.
Mechanism of Action
Pharmacologic Class:
Cholinergic Nicotinic Agonist
Indications (2)
Worked on NICORETTE (MINT) at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.